The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers
Abstract Myeloid‐derived suppressor cells (MDSCs) are an immature group of myeloid‐derived cells generated from myeloid cell precursors in the bone marrow. MDSCs appear almost exclusively in pathological conditions, such as tumor progression and various inflammatory diseases. The leading function of...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | MedComm |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/mco2.323 |
| _version_ | 1797693062993936384 |
|---|---|
| author | Ruiyang Ren Chenyi Xiong Runyu Ma Yixuan Wang Tianyang Yue Jiayun Yu Bin Shao |
| author_facet | Ruiyang Ren Chenyi Xiong Runyu Ma Yixuan Wang Tianyang Yue Jiayun Yu Bin Shao |
| author_sort | Ruiyang Ren |
| collection | DOAJ |
| description | Abstract Myeloid‐derived suppressor cells (MDSCs) are an immature group of myeloid‐derived cells generated from myeloid cell precursors in the bone marrow. MDSCs appear almost exclusively in pathological conditions, such as tumor progression and various inflammatory diseases. The leading function of MDSCs is their immunosuppressive ability, which plays a crucial role in tumor progression and metastasis through their immunosuppressive effects. Since MDSCs have specific molecular features, and only a tiny amount exists in physiological conditions, MDSC‐targeted therapy has become a promising research direction for tumor treatment with minimal side effects. In this review, we briefly introduce the classification, generation and maturation process, and features of MDSCs, and detail their functions under various circumstances. The present review specifically demonstrates the environmental specificity of MDSCs, highlighting the differences between MDSCs from cancer and healthy individuals, as well as tumor‐infiltrating MDSCs and circulating MDSCs. Then, we further describe recent advances in MDSC‐targeted therapies. The existing and potential targeted drugs are divided into three categories, monoclonal antibodies, small‐molecular inhibitors, and peptides. Their targeting mechanisms and characteristics have been summarized respectively. We believe that a comprehensive in‐depth understanding of MDSC‐targeted therapy could provide more possibilities for the treatment of cancer. |
| first_indexed | 2024-03-12T02:38:10Z |
| format | Article |
| id | doaj.art-410a24b7187340e2a681fbb4cb5338c9 |
| institution | Directory Open Access Journal |
| issn | 2688-2663 |
| language | English |
| last_indexed | 2024-03-12T02:38:10Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | MedComm |
| spelling | doaj.art-410a24b7187340e2a681fbb4cb5338c92023-09-04T11:20:36ZengWileyMedComm2688-26632023-08-0144n/an/a10.1002/mco2.323The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancersRuiyang Ren0Chenyi Xiong1Runyu Ma2Yixuan Wang3Tianyang Yue4Jiayun Yu5Bin Shao6State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases Department of Orthodontics West China Hospital of Stomatology Sichuan University Chengdu Sichuan ChinaState Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases West China Hospital of Stomatology Sichuan University Chengdu Sichuan ChinaState Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases West China Hospital of Stomatology Sichuan University Chengdu Sichuan ChinaState Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases West China Hospital of Stomatology Sichuan University Chengdu Sichuan ChinaState Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases West China Hospital of Stomatology Sichuan University Chengdu Sichuan ChinaDepartment of Radiotherapy Cancer Center and State Key Laboratory of Biotherapy West China Hospital Sichuan University Chengdu ChinaState Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases West China Hospital of Stomatology Sichuan University Chengdu Sichuan ChinaAbstract Myeloid‐derived suppressor cells (MDSCs) are an immature group of myeloid‐derived cells generated from myeloid cell precursors in the bone marrow. MDSCs appear almost exclusively in pathological conditions, such as tumor progression and various inflammatory diseases. The leading function of MDSCs is their immunosuppressive ability, which plays a crucial role in tumor progression and metastasis through their immunosuppressive effects. Since MDSCs have specific molecular features, and only a tiny amount exists in physiological conditions, MDSC‐targeted therapy has become a promising research direction for tumor treatment with minimal side effects. In this review, we briefly introduce the classification, generation and maturation process, and features of MDSCs, and detail their functions under various circumstances. The present review specifically demonstrates the environmental specificity of MDSCs, highlighting the differences between MDSCs from cancer and healthy individuals, as well as tumor‐infiltrating MDSCs and circulating MDSCs. Then, we further describe recent advances in MDSC‐targeted therapies. The existing and potential targeted drugs are divided into three categories, monoclonal antibodies, small‐molecular inhibitors, and peptides. Their targeting mechanisms and characteristics have been summarized respectively. We believe that a comprehensive in‐depth understanding of MDSC‐targeted therapy could provide more possibilities for the treatment of cancer.https://doi.org/10.1002/mco2.323inflammationMDSC‐targeted drugsmyeloid‐derived suppressor cellstargeted therapytumor microenvironment |
| spellingShingle | Ruiyang Ren Chenyi Xiong Runyu Ma Yixuan Wang Tianyang Yue Jiayun Yu Bin Shao The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers MedComm inflammation MDSC‐targeted drugs myeloid‐derived suppressor cells targeted therapy tumor microenvironment |
| title | The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers |
| title_full | The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers |
| title_fullStr | The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers |
| title_full_unstemmed | The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers |
| title_short | The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers |
| title_sort | recent progress of myeloid derived suppressor cell and its targeted therapies in cancers |
| topic | inflammation MDSC‐targeted drugs myeloid‐derived suppressor cells targeted therapy tumor microenvironment |
| url | https://doi.org/10.1002/mco2.323 |
| work_keys_str_mv | AT ruiyangren therecentprogressofmyeloidderivedsuppressorcellanditstargetedtherapiesincancers AT chenyixiong therecentprogressofmyeloidderivedsuppressorcellanditstargetedtherapiesincancers AT runyuma therecentprogressofmyeloidderivedsuppressorcellanditstargetedtherapiesincancers AT yixuanwang therecentprogressofmyeloidderivedsuppressorcellanditstargetedtherapiesincancers AT tianyangyue therecentprogressofmyeloidderivedsuppressorcellanditstargetedtherapiesincancers AT jiayunyu therecentprogressofmyeloidderivedsuppressorcellanditstargetedtherapiesincancers AT binshao therecentprogressofmyeloidderivedsuppressorcellanditstargetedtherapiesincancers AT ruiyangren recentprogressofmyeloidderivedsuppressorcellanditstargetedtherapiesincancers AT chenyixiong recentprogressofmyeloidderivedsuppressorcellanditstargetedtherapiesincancers AT runyuma recentprogressofmyeloidderivedsuppressorcellanditstargetedtherapiesincancers AT yixuanwang recentprogressofmyeloidderivedsuppressorcellanditstargetedtherapiesincancers AT tianyangyue recentprogressofmyeloidderivedsuppressorcellanditstargetedtherapiesincancers AT jiayunyu recentprogressofmyeloidderivedsuppressorcellanditstargetedtherapiesincancers AT binshao recentprogressofmyeloidderivedsuppressorcellanditstargetedtherapiesincancers |